Trusted Resources: Education
Scientific literature and patient education texts
Safety and Efficacy of Long-Term Diflunisal Administration in Hereditary Transthyretin (ATTR) Amyloidosis
source: Amyloid: The International Journal of Experimental and Clinical Investigation
year: 2015
authors: Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S
summary/abstract:Background:
A recent 2-year randomized controlled trial indicated that the transthyretin (TTR) tetramer stabilizer, diflunisal, inhibits polyneuropathy progression and preserves quality of life in hereditary ATTR amyloidosis. However, its long-term outcomes are unknown. Here, we report tolerance and efficacy of long-term diflunisal administration in hereditary ATTR amyloidosis.
Methods:
Diflunisal was administered orally at 500 mg/day to 40 Japanese hereditary ATTR amyloidosis patents who were not candidates for liver transplantation. The observation period ranged from 2 to 116 months (mean ± SD: 38.0 ± 31.2 months).
Results:
Diflunisal-related adverse events included deterioration of renal function and thrombocytopenia resulting in discontinuation of the drug in three patients. Orally administered diflunisal significantly increased serum TTR concentration (p = 0.001) and stabilized TTR tetramer structure in each patient. Longitudinal analyses of data collected at baseline, 24 months, and after 24 months confirmed sustaining effects of diflunisal on both neurological and cardiac functions. Notably, ulnar compound muscle action potential amplitude, cardiac wall thickness, and ejection fraction were not deteriorated after 24 months of treatment.
Conclusions:
Diflunisal was tolerated well by most hereditary ATTR amyloidosis patients, although renal function and blood cell counts must be carefully monitored. Clinical effects of diflunisal were sustained after 2 years of treatment.
organization: Shinshu University School of Medicine, JapanDOI: 10.3109/13506129.2014.997872
read more
Related Content
-
Hereditary ATTR Val122Ile Cardiac AmyloidosisHereditary ATTR amyloidosis is an inheri...
-
Dylan’s Amyloidosis Storyhttps://www.youtube.com/watch?v=G3Ec14rA...
-
ESIGENZE INSODDISFATTE nell’amiloidosi hATTRhttps://www.oneamyloidosisvoice.com/wp-c...
-
Amyloidosis Support Groups Webinar on ATTRv and ATTRwt AmyloidosisPlease join us on January 21st, 2023 fro...
-
ATTR in the Heart – ASG Webinar 1/7https://www.youtube.com/watch?v=IzC_yaqs...
-
With CRISPR Gene Editing, Unique Treatments Begin to Take off for Rare DiseasesIn February last year, Doherty — now a...
-
Unmet Needs in hATTR Amyloidosishttps://www.oneamyloidosisvoice.com/wp-c...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.